News: Pfizer Inc (PFE)

PFE on New York Consolidated

29.11USD
24 Oct 2014
Price Change (% chg)

$0.51 (+1.78%)
Prev Close
$28.60
Open
$28.80
Day's High
$29.27
Day's Low
$28.71
Volume
28,424,946
Avg. Vol
25,326,488
52-wk High
$32.96
52-wk Low
$27.51

Search Stocks
Select another date:

Fri, Oct 24 2014

Deals of the day-Mergers and acquisitions

Oct 24 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:

UPDATE 1-AstraZeneca cancer drug pipeline gets boost from European green light

* EMA also backs new drugs from Pfizer, Baxter, Clinuvel (Adds AstraZeneca comment, further details)

Pfizer's $11 billion buyback plan deflates AstraZeneca bid hopes

LONDON/NEW YORK - U.S. drugmaker Pfizer is to continue buying back stock, with the board authorizing a new $11 billion share repurchase plan, deflating expectations that it will make a new bid for AstraZeneca.

Pfizer board authorizes $11 billion share repurchase

Oct 23 - Pfizer Inc on Thursday said its board of directors has authorized an $11 billion share repurchase program to be utilized over time.

U.S. court upholds patents on Pfizer's cancer drug

- A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said.

U.S. court upholds patents on Pfizer's cancer drug

Oct 23 - A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said.

UPDATE 2-Drugmakers may need indemnity for fast-tracked Ebola vaccines

* Governments or multilateral agencies may offer indemnity

FDA panel votes to keep severe warning on Pfizer anti-smoking drug

- Pfizer Inc failed to convince the U.S. Food and Drug Administration to remove a black box warning on its controversial quit-smoking drug Chantix, with an advisory panel to the agency voting against the removal on Thursday.

UPDATE 1-FDA panel votes to keep severe warning on Pfizer anti-smoking drug

Oct 16 - Pfizer Inc failed to convince the U.S. Food and Drug Administration to remove a black box warning on its controversial quit-smoking drug Chantix, with an advisory panel to the agency voting against the removal on Thursday.

FDA votes to keep black box warning on Pfizer anti-smoking drug

Oct 16 - Pfizer Inc failed in its attempt to remove a black box warning from its controversial quit-smoking drug, Chantix, after an advisory panel to the U.S. Food and Drug Administration voted against the removal.

Select another date:
Search Stocks